Cellid, Co., Ltd. Overview
Cellid is a Korean clinical-stage immunotherapy company built on CeliVax. CeliVax is a cell-based cancer vaccine platform that loads tumour antigens into a patient's own B cells and monocytes using an adenoviral vector, and adds the NKT-cell adjuvant α-galactosylceramide. The company listed on KOSDAQ in 2019 on the strength of its HPV-cancer vaccine BVAC-C.
From 2020 it redirected most of its capital into an adenovirus-vector COVID-19 vaccine. In June 2026 that vaccine (AdCLD-CoV19-1 OMI) failed to show non-inferiority to Pfizer's Comirnaty in a global Phase 3 trial. Cellid has had no meaningful drug revenue since listing. Its reported revenue now comes almost entirely from ForBaker, a bakery e-commerce business it absorbed in 2024 to meet KOSDAQ revenue-maintenance thresholds.
With cash falling, short-term borrowings rising and its lead asset impaired, Cellid agreed in September 2026 to cede control to Huniverse Global. Huniverse is a medical-IT company backed by Korea University's technology holding company and plans data-driven personalised cancer vaccines.
What the company does
Cellid runs three activities. The first, R&D, is its reason for existing. The second produces nearly all of its revenue. The third is small and still developing.
-
Biopharmaceutical R&D (core, pre-revenue).
-
CeliVax-based therapeutic cancer vaccines (the BVAC family).
-
Adenovirus-vector prophylactic vaccines, mainly COVID-19.
-
The platform uses autologous B cells and monocytes as antigen-presenting cells. Antigen genes are delivered by a replication-incompetent adenovirus, and α-galactosylceramide is added to activate NKT cells.
-
Manufacturing takes about one day per batch (company disclosure at IPO, 2019).
-
-
E-commerce / bakery (revenue-generating). This is the ForBaker business, acquired in March 2024 for about KRW 12 and merged by absorption in 2024. It produced 91.4% of FY2024 revenue and about 99.97% of FY2025 revenue.
-
Contract manufacturing / CDMO services (emerging, immaterial).
-
GMP production and quality-analysis services for viral vectors and cell and gene therapies, run from the Seongnam GMP centre.
-
CMO revenue was KRW 3.15 in Q1 2024 and only KRW 0.03 in Q1 2025.
-
A June 2025 MOU with AltiCure led to a stability-testing and product-storage contract on 2 Sep 2026. The contract value was not disclosed.
-
Business and revenue model
| Revenue type | Status | Evidence |
|---|---|---|
| Product sales (drugs) | None. No product has been approved. | Revenue was KRW 0 in FY2023 (DART) |
| Licensing / milestones | Historic upfront payments only: KRW 10 from LG Chem (2021) and an early US-only BVAC-C licence to NeoImmuneTech (2014). Milestones of up to KRW 1,825 from LG Chem are contingent. | Company release, 26 May 2021 |
| Contract manufacturing (CMO/CDMO) | Sporadic and small | 8.6% of FY2024 revenue; 0.2% of Q1 2025 revenue |
| Merchandise (bakery e-commerce) | About 100% of current revenue | FY2025 revenue of KRW 88.4, almost all e-commerce |
| Subscription | — | — |
Value-chain position and customers
Cellid sits at the discovery, translational and clinical-development stages of the biopharma value chain. It also has in-house GMP manufacturing for clinical supply.
Its intended end customers are:
-
Oncology patients and hospitals, for HPV-positive cervical, head-and-neck and other cancers.
-
National immunisation and booster programmes, for COVID-19. The company had said it would target developing countries with a lower-cost adenoviral vaccine.
-
Biotech developers that need viral-vector CDMO services.
The bakery segment sells to consumers through online channels.
Company self-description vs. independent characterisation
Company self-description (paraphrased): a "leader in cell-based immunotherapy" that develops immunotherapeutic vaccines for cancer and infectious diseases on its proprietary CeliVax platform.
Independent characterisation: Cellid is a capital-constrained, single-platform biotech whose most advanced programme has failed. It has relied on four equity raises in four years (2023–2026), a bakery acquisition to stay above KOSDAQ revenue thresholds, and now a change of control.
What remains of scientific value is concentrated in three areas:
-
BVAC-C plus durvalumab in second-line cervical cancer.
-
BVAC-E6E7 in HPV-positive head-and-neck cancer.
-
The LG Chem-partnered neoantigen programme (BVAC-Neo), which is still preclinical.
Strategy
Stated strategy themes (company statements, paraphrased)
2019 IPO: become a global immunotherapy company through the CeliVax platform. Out-license one asset a year from 2019 to 2022 (BVAC-Neo in 2019, BVAC-B in 2020). Seek conditional approval of BVAC-C by 2021.
2020–2025: achieve "vaccine sovereignty" for Korea with a domestically developed adenoviral COVID-19 vaccine priced at less than half of mRNA vaccines and aimed at developing markets. Seek MFDS and WHO approvals.
2024 onward: "select and focus" on the programmes most likely to succeed. Diversify revenue through bakery and potential health functional foods. Stabilise earnings through CMO/CDMO.
Delivery against targets: none of the 2019 out-licensing targets were met on time. The BVAC-Neo licence to LG Chem came in 2021. BVAC-C did not reach conditional approval by 2021, and the COVID-19 vaccine failed Phase 3.
Initiatives in the last 24 months
| Initiative | Date | Details | Status |
|---|---|---|---|
| Omicron COVID-19 Phase 3 completion and approval filing | 2025 – Jun 2026 | Planned MFDS filing (as stated on 18 Jun 2026) | Failed (26 Jun 2026). The company says it is reviewing a supplementary trial. |
| LP.8.1 strain-updated booster | 2,026 | Phase 2 IND | Returned/rejected by the regulator |
| Viral-vector CDMO "one-stop" platform with AltiCure | MOU 16 Jun 2025; first contract 2 Sep 2026 | Joint R&D-to-GMP offering; localisation of vector technology | Early stage; contract value undisclosed |
| BVAC-E6E7 head-and-neck Phase 1 | 2024–2026 | Selected as a government-funded national project | Ongoing |
| Magok HQ and R&D centre | 2023–2026 | KRW 235.4 consortium investment through PF | Completed |
| Change of control to Huniverse Global; personalised cancer vaccines using medical data | Signed 21 Sep 2026 | Huniverse's precision-medicine hospital information system and data infrastructure to be combined with the BVAC pipeline; joint platform; KRW 100 to fund existing R&D, clinical trials and the platform; further CB financing planned | Pending (payment due 9 Nov 2026) |
| Bakery-to-health-food pivot | Stated Jun 2024 | Possible conversion of the bakery business into health functional foods | No disclosed progress |
ESG commitments: none disclosed.
Cost programmes: none with quantified targets were disclosed.
Medium-term targets and guidance
No quantitative financial guidance is publicly disclosed. Management has given no revenue, breakeven or cash-runway guidance in the sources reviewed.
Products & Services
Platform technologies
| Platform | Description | Status |
|---|---|---|
| CeliVax | Autologous B cells and monocytes are transduced with antigen genes by adenovirus and loaded with α-galactosylceramide, which activates NKT cells. The aim is to engage innate immunity (NK/NKT) and adaptive immunity (CD8+ T cells, antibodies) together. Manufacturing takes about one day. | Core oncology platform. Clinical proof of concept in cervical cancer. |
| Replication-incompetent adenovirus vector platform | Proprietary adenoviral vector and high-yield producer cell line. Used for prophylactic vaccines and as the CeliVax gene-delivery tool. | Supported the COVID-19 programme. Now marketed for CDMO use. |
| GMP CDMO capability | GMP-grade production of viral vectors and cell and gene therapies, plus quality-control analytics | Early commercialisation (AltiCure contract, 2026) |
Oncology pipeline (BVAC family, CeliVax-based)
| Product | Antigen / target | Indications | Stage (latest disclosed) | Key data | Partner |
|---|---|---|---|---|---|
| BVAC-C (monotherapy and + topotecan) | HPV16/18 E6/E7 | Recurrent/metastatic cervical cancer after platinum chemotherapy | Phase 1/2a completed (NCT02866006) | ORR 21% (n=14), median DoR 18 months, DCR 43% (ASCO 2021). Peer-reviewed in Frontiers in Immunology (2024). | US rights historically licensed to NeoImmuneTech (2014). |
| BVAC-C + durvalumab (DURBAC) | HPV16/18 E6/E7 + anti-PD-L1 | Second-line HPV16/18+ cervical cancer | Phase 2 (NCT04800978); six Korean centres | ORR 37.9% (5 CR, 6 PR), median PFS 8.7 months, 6-month PFS 51.7%; ORR 52.9% if treatment-free interval >6 months; grade 3–4 AEs 13% (SGO 2025) | Durvalumab is AstraZeneca's drug. Supply arrangement not detailed in sources. |
| BVAC-E6E7 | HPV16/18 E6/E7 (next-generation construct) | Unresectable recurrent/metastatic HPV16/18+ head-and-neck squamous cell carcinoma | Phase 1, under a selected national R&D grant | Not yet reported | — |
| BVAC-B | HER2/neu | HER2+ gastric cancer; planned breast, ovarian, lung, pancreatic | Phase 1 approved Jan 2018 (Severance). reported as deprioritised under a 2024 "select and focus" strategy. | — | — |
| BVAC-P | PAP, PSMA | Prostate cancer, renal cell carcinoma, glioblastoma | Preclinical (2019 disclosure) | — | — |
| BVAC-M | gp100 / MAGE-A3 | Melanoma, lung and colorectal cancer | Preclinical (2019 disclosure) | — | — |
| BVAC-Neo | Patient-specific neoantigens | Pan-tumour personalised vaccine | Preclinical. A third-party report says there has been no clinical entry about five years after licensing. | — | LG Chem (global exclusive, 2021). Syntekabio AI-prediction MOU (2019). |
Infectious-disease pipeline (adenovirus vector)
| Product | Description | Stage | Key data |
|---|---|---|---|
| AdCLD-CoV19 (original) | Single-dose adenoviral COVID-19 vaccine | Phase 1/2a IND Dec 2020. Superseded. | Strong antibody responses in mouse and monkey studies (company, 2020) |
| AdCLD-CoV19-1 | Improved-productivity vector version | Phase 2b terminated early in 2022 | Recruitment failure |
| AdCLD-CoV19-1 OMI | Omicron booster | Global Phase 3 completed. Primary endpoint missed (26 Jun 2026). | GMT ratio 0.42 vs. Comirnaty (lower 95% CI 0.38 vs. non-inferiority margin 0.67). Seroresponse 17.12% vs. 42.64% (difference −25.51 pp vs. −10 pp margin). No serious ADRs reported. Planned enrolment was 4,000 (Cohort A 1,200 immunogenicity; Cohort B 2,800 safety). |
| AdCLD-CoV19-1 LP.8.1 | Strain-updated booster | Phase 2 IND filed and returned/rejected in 2026 | — |
| Multivalent COVID-19 vaccine | Mentioned as a use of 2023 rights-offering funds | Status not disclosed | — |
Non-pharma products and services
| Offering | Description | Target customer | Pricing |
|---|---|---|---|
| ForBaker bakery products (e-commerce) | Bakery franchise and online sales. | Consumers | — |
| CDMO services | Viral-vector GMP production, stability testing, product storage | Biotech and gene-therapy developers (e.g. AltiCure) | Contract values not disclosed |
Financial Narrative
Source for all tables: OpenDART separate statements via Valueline, Bullstory and ETFShopping, unless stated otherwise. FY = calendar year. Units are KRW 100M unless stated otherwise.
Income statement
Notes:
-
Pre-tax income equals net income because no income-tax expense was recorded.
-
Diluted EPS equals basic EPS because the company is loss-making (anti-dilutive).
-
The FY2022 net loss (−229) is far larger than the operating loss (−149), pointing to roughly KRW 80 of non-operating losses.
-
Exact FY2025 values: revenue KRW 8,841,828,282; operating income −KRW 11,343,055,983; net income −KRW 12,069,197,070 (OpenDART via Bullstory).
Margins and growth
Operating and EBITDA margins are derived. FY2023 margins are undefined because revenue was zero.
Revenue CAGR FY2021–FY2025: about 77% a year (derived: 9.1 → 88.4). This number is not meaningful as a growth measure. It reflects a switch from occasional CMO income to bakery e-commerce, not commercial progress in the pharmaceutical business.
Interim (TTM to 30 Jun 2026, Valueline):
-
Revenue KRW 104.2 and operating loss KRW −103.4.
-
Net loss KRW −273.8, including KRW 171.2 of asset impairment.
-
H1 2026 net loss is about KRW −205. This is derived from the fall in retained earnings from −770.7 to −975.7.
-
Development-cost assets fell from KRW 288.5 to KRW 147.0, consistent with impairment of capitalised COVID-19 vaccine development after the Phase 3 failure.
Balance sheet
Notes:
-
Net debt and working capital are derived.
-
FY2021 cash comes from ETFShopping.
Cash flow
Notes:
-
Equity raises come from DailyPharm (Sep 2026) and the MedigateNews and Asiae deal coverage.
-
Capex and free cash flow: not publicly disclosed in the sources reviewed. Proxies are the rise in construction-in-progress (KRW 4.3 → 68.4 → 135.1 → 280.1, FY2022–FY2025) and the final Magok investment of KRW 235.4 (DART). Free cash flow was clearly and materially negative in every year.
-
TTM operating cash flow to Q1 2026 was −77.3 (Valueline).
Ratios
Notes:
-
ROE, ROA, debt-to-equity and asset turnover are derived using average balances.
-
Liabilities-to-equity comes from ETFShopping.
-
Not meaningful: ROIC, net debt/EBITDA and interest coverage are all n/m because EBIT and EBITDA are negative. FY2025 interest expense was KRW 1.4 and interest income KRW 3.2 (Valueline).
-
Cash conversion cycle: not publicly disclosed. FY2025 inventory was KRW 1.9 and trade receivables KRW 3.1, both immaterial.
Commentary on trends, inflections and drivers
Structural loss rate. Operating losses have stayed in a narrow band of KRW 113–149 a year for five years. The improvement since FY2022 reflects two things:
-
Bakery gross profit (about KRW 15.7 in FY2025).
-
Capitalisation of COVID-19 Phase 3 costs. Development-cost assets rose from KRW 41.5 in FY2023 to KRW 288.5 in FY2025, so a large share of real R&D spending bypassed the income statement.
That capitalisation reversed in H1 2026. The impairment pushed the TTM net loss to about KRW −274. Reported losses in FY2023–FY2025 understated true economic cash burn, which was about KRW 100 a year in operating cash outflow plus capitalised development spend.
Funding dependence. Operating cash flow was negative by KRW 71–122 every year. Cash has been rebuilt only by raising capital:
-
IPO 2019: KRW 396.
-
CB 2021: KRW 190.
-
Rights issues 2023–2025: KRW 765 in total.
-
Placements in 2026: KRW 30 to investment associations and about KRW 100 from Huniverse.
Cumulative capital raised since the IPO is about KRW 1,349 (DailyPharm). The share count nearly tripled, from 10.71M to 29.50M, between FY2022 and FY2025.
Leverage inflection. The Magok HQ and R&D centre is a 22% consortium stake financed through project financing. It moved the balance sheet from net cash to net debt. Short-term borrowings jumped from zero (FY2024) to KRW 276.1 (FY2025) and KRW 336.3 (June 2026), probably reclassified from long-term debt as the project completed.
With cash at KRW 129.7 at June 2026, the current ratio has fallen to 0.57x. That makes refinancing, or selling or leasing out space at the Magok asset, an urgent issue. This is an analytical inference; the company has not disclosed a refinancing plan in the sources reviewed.
Equity erosion. Equity peaked at KRW 742 at FY2025 after the 2025 raise, then fell 28% in six months to KRW 536.7 because of the impairment. The FY2023 land revaluation surplus of KRW 119.7 supports book value. Price-to-book of about 1.2–1.3x therefore partly rests on revalued land.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (KRW) and Revenue by Segment (%)
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
E-commerce (bakery) revenue (KRW 100M) | 0 | 0 | 0 | 38.1 | 88.4 |
Bio / CMO revenue (KRW 100M) | 9.1 | 4.8 | 0 | 3.6 | 0.03 |
Total revenue (KRW 100M) | 9.1 | 4.8 | 0 | 41.7 | 88.4 |
E-commerce share of revenue (%) | 0 | 0 | 0 | 91.4 | 99.97 |
Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total revenue YoY growth (%) | n/m | 112.3 |
Company gross margin (%) | — | 17.8 |
E-commerce operating margin (%) | — | -2 |
Income Statement (KRW) and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 9.1 | 4.8 | 0 | 41.7 | 88.4 |
Cost of sales (KRW 100M) | — | — | — | — | 72.6 |
Gross profit (KRW 100M) | — | — | — | — | 15.7 |
SG&A incl. expensed R&D (KRW 100M) | — | — | — | — | 129.1 |
Operating income (KRW 100M) | -130 | -149 | -122 | -120 | -113 |
EBITDA (KRW 100M) | — | — | — | — | -97.3 |
Pre-tax income (KRW 100M) | -131 | -229 | -116 | -123 | -121 |
Net income (KRW 100M) | -131 | -229 | -116 | -123 | -121 |
EPS basic (KRW) | -1,346 | -2,350 | -1,078 | -743 | -474 |
EPS diluted (KRW) | -1,346 | -2,350 | -1,078 | -743 | -474 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | — | 17.8 |
Operating margin (%) | -1,430 | -3,104 | — | -288 | -128 |
EBITDA margin (%) | — | — | — | — | -110 |
Net margin (%) | -1,438 | -4,764 | — | -294 | -137 |
Revenue growth YoY (%) | — | -47.2 | -100 | — | 112.3 |
Balance Sheet (KRW) and Share Count (M)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW 100M) | — | 458.5 | 639.2 | 760.8 | 1,108.6 |
Cash & equivalents (KRW 100M) | 52 | 82.5 | 133.8 | 90.2 | 223.5 |
Current assets (KRW 100M) | — | 209.7 | 168.7 | 114.5 | 244.2 |
Current liabilities (KRW 100M) | — | 205.3 | 103.2 | 49.4 | 294.2 |
Short-term debt incl. ST bonds (KRW 100M) | — | 118.7 | 54.9 | 0 | 276.1 |
Long-term borrowings (KRW 100M) | — | 0 | 64.8 | 130.7 | 0 |
Total debt (KRW 100M) | — | 118.7 | 119.7 | 130.7 | 276.1 |
Net debt (KRW 100M) | — | 36.2 | -14.1 | 40.5 | 52.6 |
Total liabilities (KRW 100M) | — | 234.1 | 234.2 | 248.8 | 366.6 |
Total equity (KRW 100M) | — | 224.3 | 404.9 | 512.0 | 742.0 |
Goodwill (KRW 100M) | — | 0 | 0 | 8.8 | 0 |
Capitalised development costs (KRW 100M) | — | 0 | 41.5 | 185.3 | 288.5 |
Property, plant & equipment (KRW 100M) | — | 206.1 | 403.3 | 446.2 | 568.5 |
Working capital (KRW 100M) | — | 4.4 | 65.5 | 65.1 | -50.0 |
Accumulated deficit (KRW 100M) | — | -410.3 | -526.9 | -650.2 | -770.7 |
Shares outstanding (M) | 10.71 | 10.71 | 13.60 | 21.10 | 29.50 |
Book value per share (KRW) | — | 2,096 | 2,977 | 2,426 | 2,515 |
Financial Analysis
| Item | KRW 100M |
|---|---|
Total assets | 968.3 |
Cash | 129.7 |
Current assets | 205.9 |
Current liabilities | 358.2 |
Short-term borrowings | 336.3 |
Total liabilities | 431.5 |
Equity | 536.7 |
Buildings (Magok, capitalised) | 366.9 |
Development costs | 147.0 |
Working capital (derived) | −152.3 |
Net debt (derived) | 206.6 |
BPS | KRW 1,819 |
Cash Flow (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW 100M) | -82 | -122 | -71 | -103 | -102 |
Equity raised (KRW 100M, approx.) | 0 | 0 | 175 | 232 | 358 |
Convertible bonds issued (KRW 100M) | 190 | 0 | 0 | 0 | 0 |
Dividends paid (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | — | — | -36.9 | -26.8 | -19.3 |
ROA (%) | — | — | -21.1 | -17.6 | -12.9 |
Current ratio (x) | — | 1.02 | 1.63 | 2.32 | 0.83 |
Liabilities-to-equity (%) | 50 | 104 | 58 | 49 | 49 |
Debt-to-equity (x) | — | 0.53 | 0.30 | 0.26 | 0.37 |
Asset turnover (x) | — | — | 0 | 0.06 | 0.09 |
Revenue by Region (KRW) and Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
South Korea revenue (KRW 100M) | 9.1 | 4.8 | 0 | 41.7 | 88.4 |
Overseas revenue (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
South Korea share of revenue (%) | 100 | 100 | 100 | 100 | 100 |
Revenue by Region (KRW)
| Segment × region | FY2024 | FY2025 |
|---|---|---|
E-commerce × Korea (KRW 100M) | 38.1 | 88.4 |
Bio/CMO × Korea (KRW 100M) | 3.6 | 0.03 |
Share Price History
| Date | Price (KRW) | Context |
|---|---|---|
20 Feb 2019 | 33,000 (IPO); 43,750 (opening) | Listing |
Jul 2021 | About 143,103 close (9 Jul 2021); intraday above 150,000 | COVID-19 vaccine peak; market cap above KRW 13,000 |
31 Dec 2025 | 2,860 | Year-end |
30 Apr 2026 | 3,180 | Before the readout |
30 Jun 2026 | 1,406 | After the Phase 3 failure |
20 Jul 2026 | 1,071 | Near the 52-week low |
15 Oct 2026 | 2,215 | Latest close |
Valuation Multiples
| Multiple | Cellid | Peer median | Note |
|---|---|---|---|
P/E | n/m | n/m | Loss-making |
EV/EBITDA | n/m | n/m | Negative EBITDA |
EV/Sales (TTM, approx.) | 8.2 | — | Derived: (market cap about 653 + net debt about 207) / TTM revenue 104.2 |
P/S (FY2025) | 7.4 | 3.8 | Derived: 653 / 88.4. Peer median from Alpha Distillery. |
P/B (June 2026 equity) | 1.22 | 0.93 | Derived: 653 / 536.7 |
Components
| Component | Value (KRW 100M) |
|---|---|
E-commerce | 28 |
BVAC-C | 220 |
BVAC-E6E7 | 80 |
COVID-19 residual | 50 |
Sum of the parts | 378 |
Key Events
| Event | FY2019 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capital raised (KRW 100M) | 396 | 190 | 175 | 232 | 358 |
Issue price (KRW) | 33,000 | — | 4,515 | 3,090 | 4,260 |
Analyst Conclusions
Guidance and consensus
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue (KRW 100M) | 95 | 105 |
| Operating loss (KRW 100M) | -105 | -95 |
Management guidance: none quantitative. The company has said it will continue COVID-19 development based on the safety data and is reviewing a supplementary immunogenicity trial. After closing, Huniverse plans to fund existing R&D, clinical trials and a joint platform with the KRW 100 subscription and further CB financing.
Consensus: none available.
Independent AI estimates (Alpha Distillery, labelled): ### Bull-case arguments
-
BVAC-C has real activity. The ORR of 37.9% and 6-month PFS of 51.7% in a second-line, post-platinum population leave room for a partnered registrational study, especially in patients with a treatment-free interval of more than 6 months (ORR 52.9%).
-
The recapitalisation removes the overhang. About KRW 130 of fresh equity (Huniverse plus Centrust/SPE) and a planned CB could ease the June 2026 liquidity squeeze. A new board may also cut spending on the failed COVID-19 franchise.
-
Hard-asset backstop. Land of KRW 233.8 and a Magok building of KRW 366.9 support book value. Asset monetisation could cut short-term debt and lift the effective cash runway.
Bear-case arguments
-
The core thesis has failed. About KRW 955 was spent on COVID-19 after 2020 without approval. The GMT ratio of 0.42 is not a near-miss, and the follow-on LP.8.1 IND was already rejected.
-
Balance-sheet fragility. A current ratio of 0.57x, KRW 336.3 of short-term debt and operating cash burn of about KRW 100 a year mean more dilution is likely even after closing. The acquirer itself has equity of only KRW 8.
-
Valuation does not reflect fundamentals. P/S of about 7.4x on bakery revenue with negative operating margins, and P/B of about 1.2x despite equity erosion. Pricing has been driven by themes (limit-up and limit-down moves) rather than cash flows.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 9 Nov 2026 | Huniverse subscription payment (deal closing); board reconstitution; new CEO |
| Q4 2026 – H1 2027 | Terms and size of the follow-on CB |
| Q4 2026 | Q3 2026 quarterly report: cash, borrowings, further impairment of the remaining KRW 147.0 of development costs |
| 2,027 | Supplementary COVID-19 trial decision, or a formal discontinuation |
| 2026–2027 | BVAC-C registrational strategy or partnering; DURBAC survival update; BVAC-E6E7 Phase 1 data |
| 2026–2027 | Any clinical entry of LG Chem's BVAC-Neo, or termination of the licence |
| Ongoing | Refinancing of short-term borrowings or a transaction on the Magok asset |
| Ongoing | Additional CDMO contracts with disclosed values |
| Mar 2027 | FY2026 business report; KOSDAQ listing-maintenance status |
Analyst verdict
Cellid is a clear example of a Korean technology-listed biotech that bet its balance sheet on a pandemic opportunity and lost.
The original CeliVax thesis was a fast-to-manufacture, autologous B-cell and monocyte vaccine that engages innate and adaptive immunity. That idea still has scientific merit. The best evidence is DURBAC, where BVAC-C plus durvalumab produced a 37.9% response rate and an 8.7-month median PFS in second-line HPV16/18-positive cervical cancer.
Most of the company's capital and attention since 2020, however, went to an adenoviral COVID-19 booster. It changed form three times and finally failed non-inferiority against Comirnaty by a wide margin in June 2026. The financial consequences are now clear:
-
An impairment of about KRW 162.
-
Equity down 28% in six months.
-
KRW 336 of short-term borrowings against KRW 130 of cash.
-
Revenue that comes from a bakery rather than medicine.
The Huniverse transaction is best understood as survival financing with a strategic narrative attached. Combining hospital-data infrastructure with personalised vaccines is a plausible long-term idea. But the acquirer is small (equity of KRW 8), has no development experience, and has not yet named product candidates or timelines. Value creation will depend on three things:
-
Disciplined capital allocation. That likely means formally winding down the COVID-19 programme and refinancing or monetising the Magok asset.
-
Advancing BVAC-C with a partner, ideally one that owns a checkpoint inhibitor.
-
Converting GMP capacity into contracts with disclosed values.
At about KRW 2,215 the market prices Cellid at roughly 1.2x June 2026 book and 7.4x bakery-dominated sales. That premium to Korean peers appears driven by theme trading rather than fundamentals. On the evidence available, the risk/reward is unfavourable until three things happen: the deal closes, the post-closing capital structure is disclosed, and a credible, funded registrational plan for BVAC-C is presented.
Stance: Negative / high-risk speculative. The view should be re-assessed on deal closing and on the Q3 2026 balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Kang Chang-yul (강창율) | Founder, CEO and largest shareholder (until the Huniverse closing) | Since 2006 | Professor at SNU College of Pharmacy. Founding member of IDEC Pharmaceuticals (now Biogen) and contributor to the development of Rituxan. | Individual pay not disclosed in sources reviewed. Korean rules require disclosure only above KRW 5 a year. |
Oh Tae-kwon (오태권) | Head of research institute | Named at the 2019 IPO | — | — |
Kang Su-yeon (강수연) | Managing director (전무) | Named at the 2019 IPO | — | — |
Jang Kyung-hee (장경희) | Executive director (상무) | Named at the 2019 IPO | — | — |
Jung Se-hyun (정세현) | Executive director, management support | Named in a July 2022 filing | — | — |
Kim Min-su (김민수) | Head of IR/finance team | Named in a 2020 release | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Kang Chang-yul | 19.42% | End-2019 (DailyPharm) |
Kang Chang-yul (with related parties) | 15.02% (21.1%) | May 2024 (Smart Today; Asiae) |
Kang Chang-yul | 8.27% | 30 Jun 2026 (DailyPharm) |
Minority shareholders (30,678 holders) | 89.03% | 31 Dec 2025 (FY2025 business report via ETFShopping) |
Foreign investors | 0.93% | Sep 2026 (Alpha Distillery) |
Huniverse Global (pro forma) | About 13.5% | Derived: 4,796,163 shares out of about 35.63M post-issuance shares (29.50M + 1.33M + 4.80M). The final figure depends on the CB and any other issuance. |
Kang Chang-yul (pro forma) | About 6.9% | Derived |
Centrust Investment Association / SPE Partners Investment Association | About 1.9% each (666,666 shares each) | Derived from the 22 Sep 2026 allotment |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Relevant asset / position |
|---|---|---|---|
HPV-driven cancer therapeutic vaccines | Genexine | Korea | GX-188E (HPV DNA vaccine) combined with a PD-1 inhibitor in cervical cancer. The most direct Korean comparator. |
HPV-driven cancer therapeutic vaccines | Inovio Pharmaceuticals | US | VGX-3100 / INO-3107 HPV DNA immunotherapies |
HPV-driven cancer therapeutic vaccines | ISA Pharmaceuticals | Netherlands | ISA101b synthetic long-peptide HPV16 vaccine + PD-1 |
HPV-driven cancer therapeutic vaccines | PDS Biotechnology | US | PDS0101 HPV16 vaccine in head-and-neck cancer |
Personalised neoantigen vaccines | Moderna / Merck | US | mRNA-4157 (intismeran autogene) |
Personalised neoantigen vaccines | BioNTech / Genentech | Germany / US | Autogene cevumeran |
Cell-based immuno-oncology (Korea) | Eutilex | Korea | Immune-cell therapy (cited as a peer) |
Cell-based immuno-oncology (Korea) | VaxCell-Bio, GC Cell | Korea | NK / cell therapies |
Oncolytic / immuno-oncology (Korea) | SillaJen, PharmAbcine, ImmuneOncia | Korea | Peers in Korean immuno-oncology trading baskets |
COVID-19 vaccines | Pfizer/BioNTech, Moderna, Novavax, SK bioscience (SKYCovione), EuBiologics | Global / Korea | Approved incumbents. Pfizer's Comirnaty was the Phase 3 comparator Cellid failed against. |
Viral-vector CDMO (Korea) | Binex, AltiCure, SK pharmteco, ENCell, CHA Biotech's affiliates | Korea | Competitors (and partners) in the CDMO market |
Key Competitors
| Company | Ticker | P/B (x) | P/S (x) | Operating margin (%) | Note |
|---|---|---|---|---|---|
Cellid | 299,660 | 1.42 | 7.58 | -128.3 | Phase 3 failed; revenue is mostly bakery |
Genematrix (진매트릭스) | 109,820 | 1.15 | 3.5 | -25.4 | COVID-19 diagnostics residual |
Eutilex | 263,050 | 0.71 | 5.2 | -180.3 | Immune-cell therapy; clinical delays |
SillaJen | 215,600 | 0.85 | 3.2 | Near breakeven | Oncolytic virus |
PharmAbcine | 208,340 | 1.02 | 3.3 | -95.1 | Early immuno-oncology |
Peer median | — | 0.93 | 3.8 | -95 | — |



